These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 29028589)

  • 1. TanshinoneIIA enhances the chemosensitivity of breast cancer cells to doxorubicin through down-regulating the expression of MDR-related ABC transporters.
    Li K; Lai H
    Biomed Pharmacother; 2017 Dec; 96():371-377. PubMed ID: 29028589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of tanshinone IIA and doxorubicin possesses synergism and attenuation effects on doxorubicin in the treatment of breast cancer.
    Li K; Liu W; Zhao Q; Wu C; Fan C; Lai H; Li S
    Phytother Res; 2019 Jun; 33(6):1658-1669. PubMed ID: 30945389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of β-elemene on the kinetics of intracellular transport of d-luciferin potassium salt (ABC substrate) in doxorubicin-resistant breast cancer cells and the associated molecular mechanism.
    Tang CY; Zhu LX; Yu JD; Chen Z; Gu MC; Mu CF; Liu Q; Xiong Y
    Eur J Pharm Sci; 2018 Jul; 120():20-29. PubMed ID: 29704644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quercetin enhances chemotherapeutic effect of doxorubicin against human breast cancer cells while reducing toxic side effects of it.
    Li S; Yuan S; Zhao Q; Wang B; Wang X; Li K
    Biomed Pharmacother; 2018 Apr; 100():441-447. PubMed ID: 29475141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tanshinone IIA potentiates the chemotherapeutic effect of doxorubicin against breast cancer cells and attenuates the cardiotoxicity of doxorubicin by regulating ERK1/2 pathway.
    Li S; FeiyuTeng ; Zhang J; Zhang P; Li M; Wang X; Li K
    J Biochem Mol Toxicol; 2024 Oct; 38(10):e23851. PubMed ID: 39267350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quercetin reversed MDR in breast cancer cells through down-regulating P-gp expression and eliminating cancer stem cells mediated by YB-1 nuclear translocation.
    Li S; Zhao Q; Wang B; Yuan S; Wang X; Li K
    Phytother Res; 2018 Aug; 32(8):1530-1536. PubMed ID: 29635751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
    Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
    Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ATP-dependent activity and mitochondrial localization of drug efflux pumps in doxorubicin-resistant breast cancer cells.
    Dartier J; Lemaitre E; Chourpa I; Goupille C; Servais S; Chevalier S; Mahéo K; Dumas JF
    Biochim Biophys Acta Gen Subj; 2017 May; 1861(5 Pt A):1075-1084. PubMed ID: 28214549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small-molecule synthetic compound norcantharidin reverses multi-drug resistance by regulating Sonic hedgehog signaling in human breast cancer cells.
    Chen YJ; Kuo CD; Chen SH; Chen WJ; Huang WC; Chao KS; Liao HF
    PLoS One; 2012; 7(5):e37006. PubMed ID: 22615870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
    Wang TX; Yang XH
    Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NFκBP65 transcription factor modulates resistance to doxorubicin through ABC transporters in breast cancer.
    Velaei K; Samadi N; Soltani S; Barazvan B; Soleimani Rad J
    Breast Cancer; 2017 Jul; 24(4):552-561. PubMed ID: 27878697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin.
    Xue C; Wang C; Sun Y; Meng Q; Liu Z; Huo X; Sun P; Sun H; Ma X; Ma X; Peng J; Liu K
    Oncotarget; 2017 Jan; 8(5):8622-8632. PubMed ID: 28052008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of P-glycoprotein-mediated multidrug resistance is induced by saikosaponin D in breast cancer MCF-7/adriamycin cells.
    Li C; Guan X; Xue H; Wang P; Wang M; Gai X
    Pathol Res Pract; 2017 Jul; 213(7):848-853. PubMed ID: 28554760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular iodine impairs chemoresistance mechanisms, enhances doxorubicin retention and induces downregulation of the CD44+/CD24+ and E-cadherin+/vimentin+ subpopulations in MCF-7 cells resistant to low doses of doxorubicin.
    Bontempo A; Ugalde-Villanueva B; Delgado-González E; Rodríguez ÁL; Aceves C
    Oncol Rep; 2017 Nov; 38(5):2867-2876. PubMed ID: 28901484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lapatinib enhances the cytotoxic effects of doxorubicin in MCF-7 tumorspheres by inhibiting the drug efflux function of ABC transporters.
    Chun SY; Kwon YS; Nam KS; Kim S
    Biomed Pharmacother; 2015 May; 72():37-43. PubMed ID: 26054673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tanshinone IIA blocks epithelial-mesenchymal transition through HIF-1α downregulation, reversing hypoxia-induced chemotherapy resistance in breast cancer cell lines.
    Fu P; Du F; Chen W; Yao M; Lv K; Liu Y
    Oncol Rep; 2014 Jun; 31(6):2561-8. PubMed ID: 24737252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tanshinone II A improves the chemosensitivity of breast cancer cells to doxorubicin by inhibiting β-catenin nuclear translocation.
    Li S; Wu C; Fan C; Zhang P; Yu G; Li K
    J Biochem Mol Toxicol; 2021 Jan; 35(1):e22620. PubMed ID: 32886829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary study of the effects of β-elemene on MCF-7/ADM breast cancer stem cells.
    Dong Y; Li L; Wang L; Zhou T; Liu JW; Gao YJ
    Genet Mol Res; 2015 Mar; 14(1):2347-55. PubMed ID: 25867381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF-7/Dox breast cancer cells.
    Chakravarty G; Mathur A; Mallade P; Gerlach S; Willis J; Datta A; Srivastav S; Abdel-Mageed AB; Mondal D
    Biochimie; 2016 May; 124():53-64. PubMed ID: 26844637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. pH and redox dual-responsive nanoparticles based on disulfide-containing poly(β-amino ester) for combining chemotherapy and COX-2 inhibitor to overcome drug resistance in breast cancer.
    Zhang S; Guo N; Wan G; Zhang T; Li C; Wang Y; Wang Y; Liu Y
    J Nanobiotechnology; 2019 Oct; 17(1):109. PubMed ID: 31623608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.